Abstract 1668P
Background
There is scant attention given to the distress experienced by cancer patients or their caregivers in low-middle income countries like India. This study measures patient and caregiver distress in oncology and attempts to evaluate any correlation between the two.
Methods
All cancer patients ≥18 years and their primary caregiver were invited to participate in a survey which included demographic, disease, and therapy details, the NCCN distress scale for the patient and the Zarit Burden Interview (Short 12 items) questionnaire for the caregiver. An open-ended interview was used to record any additional problems.
Results
250 patients and corresponding caregivers completed the survey. 70.4% patients and 32.4% caregivers had moderate to severe distress burden. The average distress score for the patients and caregiver was 4.82 and 17.88 on the respective scales. Higher mean distress scores were seen in patients younger than 40 years, those from a rural background, having secondary or higher education and those on active or palliative treatment. Distress in patients was independent of gender, income group and hospital admission. Commonest care givers were sons (38.8%) and husbands (25.6%). Daughters as caregivers had the highest mean average burden (22.6). When scored individually, the question on enough time for oneself (Q1) and stress towards other responsibilities (Q2) had the highest mean scores (1.9) while the lowest average score (0.9) was found for the question regarding strain felt around patient. Open ended interview identified financial stress and sexual frustration as common causes cause of caregiver distress. On generating a scatter plot using linear regression, a definite trend was seen of rising patient distress with an increase in caregiver distress and Pearson’s Chi square test revealed a statistically significant association with the patient and caregiver distress scores (p <.0001).
Conclusions
There is significant unaddressed distress in both cancer patients and caregivers with a definite association between them. Open ended interviews also gave insight into causes of distress. Distress screening, co- counselling and early psycho-oncological interventions may help address these lacunae.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1646P - A multicohort phase II trial of androgen deprivation therapy (ADT), docetaxel (DOCE) and nivolumab (NIVO) in patients (pts) with newly diagnosed metastatic hormone sensitive prostate cancer (mHSPC) enriched for inflamed tumours and DNA damage repair (DDR) alterations: Cohort 3 results
Presenter: Xiao Wei
Session: Poster session 11
1647P - Clinical validity of plasma DNA testing to identify BRCA-mutated (BRCA+) patients in the MAGNITUDE study
Presenter: Gerhardt Attard
Session: Poster session 11
1649P - Impact of concomitant medications on safety in patients with high-volume metastatic hormone-sensitive prostate cancer (mHSPC) receiving rezvilutamide (Rez) plus androgen-deprivation therapy (ADT): A post-hoc analysis of the randomized phase III CHART trial
Presenter: Dingwei Ye
Session: Poster session 11
1650P - Fuzuloparib plus abiraterone acetate and prednisone (AA-P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): A phase I study
Presenter: Tao Dai
Session: Poster session 11
1651P - Characteristics, tolerance and effectiveness of patients aged more or less than 75 years treated with [177Lu]Lu-PSMA-617 as part of France’s early access program
Presenter: David Tonnelet
Session: Poster session 11
1652P - SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
Presenter: Dana Rathkopf
Session: Poster session 11
1653P - Molecular and immunologic correlates of high PSMA/FOLH1 mRNA expression in prostate cancer (PC)
Presenter: Rana McKay
Session: Poster session 11
1654P - TAMARACK: Randomized Phase II trial of the B7-H3 targeting antibody drug conjugate (ADC) vobramitamab duocarmazine (vobra duo) in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Johann de Bono
Session: Poster session 11
1655P - Association of location of BRCA1/2 pathogenic variants with benefit from PARP-inhibitors in metastatic castration-resistant prostate cancers: Results from the PROGRESS study
Presenter: Lorena Incorvaia
Session: Poster session 11